Supplier News: Made Scientific, CordenPharma, WuXi XDC & More
The latest from CDMOs, CMOs, and suppliers featuring Made Scientific, CordenPharma, WuXi XDC, Kincellis, MilliporeSigma, Adragos Pharma, Codis and Sanner.
Biologics Manufacturing
* Made Scientific Acquires Cell-therapy Mfg Facility from Resilience
* WuXI XDC Advances, ADC, Conjugation and Drug-Product Site in Singapore
* Kincell Therapeutics, Cellipoint Biosciences Complete Merger
* MilliporeSigma Opens Biosafety Testing Lab in Singapore
Formulation Development/Drug Product Manufacturing
* Unither Pharmaceutical, Théa Co-Investing in New Ophthalmic Production Facility
* FSN Capital Acquires Stake in CDMO Adragos Pharma
Appointments
* CordenPharma Appoints New CEO
* Codis Appoints New Chief Commercial Officer
Packaging
* Sanner Rebrands Gilero, Expands Facility
Biologics Manufacturing
Made Scientific Acquires Cell-therapy Mfg Facility from Resilience
Made Scientific, a Princeton, New Jersey-based CDMO of cell therapies, has acquired an 85,000-square-foot clinical-to-commercial-scale cell-therapy manufacturing facility in East Norriton, Pennsylvania, from National Resilience, a CDMO of biologics, advanced therapies, and drug products.
The East Norriton facility is built for high-throughput, end-to-end cell therapy manufacturing, and includes multiple segregated GMP production areas comprising eight Grade B/C cleanrooms, one Grade C ballroom, and one Grade B fill–finish suite, alongside on-site quality control and analytical testing laboratories and high-bay warehousing. The site also holds 30,000 square feet of expansion space with a design and engineering plan supporting the build of eight additional cleanrooms for future growth and client builds. The facility supports starting material, drug substance, and drug-product manufacturing under both custom and platform technology transfer. Made Scientific will equip the site with scalable 3D bioreactor platforms (up to 200 L), advanced cell harvest equipment, automated fill–finish, and lyophilization capacity. Sponsors can begin onboarding programs now to position therapies for 2027 clinical and commercial supply.
The site and its manufacturing team have executed 145 GMP batches to date (as reported on September 21, 2026) across multiple autologous and allogeneic programs, including CAR-T and B-cell therapies.
Source: Made Scientific
Sartorius, NIBRIT Partner for Continuous Biomanufacturing Training
Sartorius, a provider of products and services for the life-sciences industry, including bioprocessing, and the National Institute for Bioprocessing Research and Training (NIBRT), a Dublin, Ireland-based bioprocessing training center, are partnering to establish a fully continuous bioprocessing center in Dublin, Ireland.
Starting in the fourth quarter of 2026, the center will serve as a hub for practical training and knowledge sharing to help the bio/pharmaceutical industry adopt intensified, digitalized, and continuous biomanufacturing processes.
As part of the collaboration, Sartorius will equip NIBRT with its Pionic technology, an end-to-end modular cGMP platform for integrated continuous bioprocessing with advanced analytics and digital tools. Through the collaboration, the new facility is expected to provide more than 1,000 scientists, engineers, and students each year with hands-on experience in intensified upstream and downstream processes.
Source: The National Institute for Bioprocessing Research and Training
WuXI XDC Advances ADC, Conjugation and Drug-Product Site in Singapore
WuXi XDC, a CDMO focused on antibody-drug conjugates (ADCs) and other bioconjugates, has achieved GMP release at its manufacturing site in Singapore
The Singapore site serves as a core of WuXi XDC’s commercial manufacturing, spanning approximately 25,000 square meters. The site’s BCM3 antibody intermediate and conjugated drug substance dual-function production line and drug-product (DP4) facility have both successfully achieved GMP release.
The BCM3 has integrated end-to-end commercial manufacturing services from antibody intermediates to conjugated drug substances. The production line supports batch sizes from 200 L to 2,000 L for antibody intermediates and up to 2,000 L for conjugated drug substances. In addition, the BCM4 facility is expected to achieve GMP release by the end of 2026, with a maximum single-batch capacity of up to 500 L of conjugated drug substance.
The DP4 facility is equipped with one 10 m² and two 30 m² lyophilizers to provide an annual production capacity of up to 8 million vials of liquid or lyophilized bioconjugates.The filling speed can reach up to 300 vials per minute. The facility offers end-to-end sterile drug product manufacturing and packaging services.
Source: WuXi XDC
Kincell Therapeutics, Cellipoint Biosciences Complete Merger
Kincell Bio, a Gainesville, Florida-based CDMO of cell therapies, and Cellipont Bioservices, a The Woodlands, Texas-based CDMO of cell therapies, have completed their merger to form Kincellis Advanced Therapies, a CDMO focused on cell therapies and other advanced modalities.
Kincellis Advanced Therapies brings together Kincell’s immune-cell technologies with Cellipont’s experience across stem cells, induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), dendritic cells, exosomes, and emerging mRNA-enabled approaches.
Kincellis operates approximately 140,000 square feet of development and manufacturing infrastructure across the following sites: Gainesville, Florida; Research Triangle Park, North Carolina; and The Woodlands, Texas. The combined network includes 16 operational, qualified GMP manufacturing suites supporting programs from early development and clinical manufacturing through commercial supply.
Source: Kincellis Advanced Therapies
MilliporeSigma Opens Biosafety Testing Lab in Singapore
MilliporeSigma, the US and Canadian life-science business of Merck KGaA, has announced the expansion of its Singapore lab to strengthen analytical and biosafety testing services.
The lab was opened in 2018, and the expansion will bring the total lab area to over 1,000 square meters. It will offer both cell-line characterization services and GMP sequencing (next-generation sequencing) capabilities. It will also offer molecular methods, including Blazar, a proprietary platform for rapid virus detection.
Source: MilliporeSigma
Formulation Development/Drug Product Manufacturing
Unither Pharmaceutical, Théa Co-Investing in New Ophthalmic Production Facility
Unither Pharmaceuticals, an Amiens, France-based CDMO focused on sterile and non-sterile liquid pharmaceutical manufacturing, and Théa, a pharmaceutical group focused on ophthalmic treatments, have announced the signing of a long-term strategic industrial partnership to develop a new ophthalmic production facility in Gannat, France, dedicated to the manufacturing of Théa’s sterile ophthalmic products.
Under the agreement, the new production unit, covering approximately 20,000 square meters, will be primarily dedicated to the manufacture of Théa’s sterile ophthalmic products. The facility was designed and will be operated by Unither Pharmaceuticals.
The first pharmaceutical validation batches are expected from 2027. Industrial operations are scheduled to begin in 2028, with the first commercial launches in 2029.
Source: Unither Pharmaceuticals
FSN Capital Acquires Stake in CDMO Adragos Pharma
FSN Capital VI, an investment firm, has acquired all remaining shares held by Prange Group, an investment firm, in Adragos Pharma Group, a Munich, Germany-based CDMO of drug products.
Following the transaction, FSN Capital VI, together with management, remains the sole shareholders in Adragos Pharma. Financial terms were not disclosed.
Source: Adragos Pharma
Appointments
CordenPharma Appoints New CEO
CordenPharma, a CDMO of drug substances and drug products, has announced the appointment of Dr. Jean-Luc Herbeaux, formerly Chief Executive Officer (CEO) of Hovione, as CEO, effective October 1, 2026. He will succeed Dr. Michael Quirmbach, who has served as CordenPharma’s CEO since 2019.
Dr. Herbeaux joins CordenPharma from Hovione, a CDMO of drug substances and drug products, where he served as CEO for more than four years. Prior to becoming CEO, he served as Chief Operating Officer at Hovione and previously held several senior roles at Evonik.
In a previous announcement, Hovione named Stefan Doboczky, currently Chairman of the Board of Directors of Hovione, CEO, effective April 1, 2027. Doboczky has served as Chairman of the Board of Directors of Hovione since 2024.
Source: CordenPharma
Codis Appoints New Chief Commercial Officer
Codis, a CDMO focused on spray drying, amorphous solid dispersions and advanced particle engineering, has announced the appointment of Steven Facer as Chief Commercial Officer.
Facer joined Codis in October 2025, bringing more than 30 years of leadership experience across pharmaceuticals, medical devices, and packaging. His global career spans senior executive roles at Thermo Fisher Scientific, ACG Worldwide, Capsugel, Catalent, Colorcon, and most recently, Adare Pharma Solutions.
Source: Codis
Packaging
Sanner Rebrands Gilero, Expands Facility
Sanner, a CDMO of healthcare packaging and medical technology products, has announced two milestones in its North American growth strategy: the rebranding of Gilero, a Durham, North Carolina-based provider of medical devices, to Sanner, and the expansion of its innovation and development facility in Chicago. The rebrand follows Sanner’s acquisition of Gilero in 2024, alongside investments in manufacturing capacity in the US.
The expanded facility features a dedicated human factors laboratory with integrated audiovisual recording for usability testing, in-house 3D printing, assembly and electromechanical prototyping capabilities, and direct access to an adjacent innovation center, which providesadvanced technologies such as CT scanning, laser cutting, and selective laser sintering 3D printing.
Source: Sanner
